43.77
price up icon1.77%   0.835
 
loading
Schlusskurs vom Vortag:
$42.93
Offen:
$45.07
24-Stunden-Volumen:
231.91K
Relative Volume:
0.50
Marktkapitalisierung:
$2.94B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-11.64
EPS:
-3.76
Netto-Cashflow:
$-157.31M
1W Leistung:
-12.02%
1M Leistung:
-15.33%
6M Leistung:
-0.07%
1J Leistung:
+84.66%
1-Tages-Spanne:
Value
$43.20
$45.76
1-Wochen-Bereich:
Value
$42.30
$50.98
52-Wochen-Spanne:
Value
$22.26
$61.61

Merus N V Stock (MRUS) Company Profile

Name
Firmenname
Merus N V
Name
Telefon
31 030 253 8800
Name
Adresse
YALELAAN 62, 3584 CM UTRECHT
Name
Mitarbeiter
229
Name
Twitter
@MerusNV
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
MRUS's Discussions on Twitter

Vergleichen Sie MRUS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
MRUS 43.65 2.94B 35.93M -244.56M -157.31M -3.76
VRTX 447.18 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.71 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.39 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.84 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.36 24.49B 3.30B -501.07M 1.03B 11.54

Merus N V Stock (MRUS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-11-02 Eingeleitet Canaccord Genuity Buy
2023-08-21 Eingeleitet TD Cowen Outperform
2022-08-02 Eingeleitet Stifel Buy
2022-02-11 Eingeleitet BMO Capital Markets Outperform
2022-02-10 Eingeleitet Needham Buy
2021-11-17 Fortgesetzt Guggenheim Buy
2021-06-07 Hochstufung Citigroup Neutral → Buy
2021-04-08 Eingeleitet William Blair Outperform
2021-03-16 Eingeleitet SVB Leerink Outperform
2020-06-26 Eingeleitet H.C. Wainwright Buy
2020-05-27 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-11-20 Fortgesetzt Guggenheim Buy
2019-06-28 Eingeleitet ROTH Capital Buy
2019-04-12 Fortgesetzt Guggenheim Buy
2019-04-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2019-03-27 Eingeleitet Berenberg Buy
2018-01-02 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-03-21 Herabstufung Citigroup Buy → Neutral
2016-12-22 Hochstufung Citigroup Neutral → Buy
2016-11-07 Herabstufung Citigroup Buy → Neutral
2016-06-13 Eingeleitet Citigroup Buy
2016-06-13 Eingeleitet Guggenheim Buy
2016-06-13 Eingeleitet Wedbush Outperform
Alle ansehen

Merus N V Aktie (MRUS) Neueste Nachrichten

pulisher
08:09 AM

The Goldman Sachs Group Initiates Coverage on Merus (NASDAQ:MRUS) - MarketBeat

08:09 AM
pulisher
Nov 20, 2024

Merus initiated with a Buy at Goldman Sachs - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

Needham & Company LLC Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat

Nov 20, 2024
pulisher
Nov 19, 2024

Merus (NASDAQ:MRUS) Shares Sold by First Turn Management LLC - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

37,426 Shares in Merus (NASDAQ:MRUS) Acquired by State of New Jersey Common Pension Fund D - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Merus is Now Oversold (MRUS) - Nasdaq

Nov 18, 2024
pulisher
Nov 18, 2024

GSA Capital Partners LLP Purchases Shares of 13,502 Merus (NASDAQ:MRUS) - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

2,054 Shares in Merus (NASDAQ:MRUS) Purchased by US Bancorp DE - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

Commodore Capital LP Bolsters Stake in Merus NV - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

SAMLYN CAPITAL, LLC Bolsters Stake in Merus NV - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

(MRUS) Trading Report - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025? - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Stake in Merus NV - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

10 Top Performing European Stocks Heading into 2025 - Insider Monkey

Nov 12, 2024
pulisher
Nov 11, 2024

Merus (NASDAQ:MRUS) Shares Bought by TimesSquare Capital Management LLC - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

US FDA extends review of Merus' gene-targeting cancer therapy - MSN

Nov 09, 2024
pulisher
Nov 08, 2024

Merus (NASDAQ:MRUS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Merus (NASDAQ:MRUS) Receives $86.70 Consensus Price Target from Brokerages - MarketBeat

Nov 08, 2024
pulisher
Nov 06, 2024

MRUSMerus N.V. Common Shares Latest Stock News & Market Updates - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Merus to Present at Upcoming Investor Conferences - The Manila Times

Nov 06, 2024
pulisher
Nov 05, 2024

Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

FDA extends review date for Merus' cancer drug Zeno - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha

Nov 05, 2024
pulisher
Nov 05, 2024

FDA extends review period for Merus's cancer drug Zeno - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Merus : FDA Extends Review of Cancer Drug Zenocutuzumab to February - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive

Nov 05, 2024
pulisher
Nov 05, 2024

Merus says FDA extended review period for cancer drug - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha

Nov 05, 2024
pulisher
Nov 05, 2024

FDA extends review period for Merus's cancer drug Zeno By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Harbor Capital Advisors Inc. Buys New Holdings in Merus (NASDAQ:MRUS) - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

abrdn plc Invests $4.36 Million in Merus (NASDAQ:MRUS) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Merus sees cash runway into 2028 - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Merus reports Q3 EPS ($1.46), consensus (88c) - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.

Nov 02, 2024
pulisher
Nov 01, 2024

Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Merus N.V. Reports Q3 2024 Financial Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Merus falls after updated data for lung cancer therapy - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire

Oct 31, 2024
pulisher
Oct 27, 2024

Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat

Oct 27, 2024
pulisher
Oct 26, 2024

Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India

Oct 25, 2024

Finanzdaten der Merus N V-Aktie (MRUS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Merus N V-Aktie (MRUS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Shuman Harry
VP Controller, PAO
Aug 20 '24
Sale
54.00
2,500
135,000
7,002
Silverman Peter B.
COO & GC
Jun 27 '24
Option Exercise
17.94
10,000
179,400
10,000
Silverman Peter B.
COO & GC
Jun 27 '24
Sale
60.00
10,000
600,000
0
Silverman Peter B.
COO & GC
Jun 17 '24
Option Exercise
24.36
62,000
1,510,280
62,000
Silverman Peter B.
COO & GC
Jun 17 '24
Sale
56.52
62,000
3,504,178
0
Shuman Harry
VP Controller, PAO
Jun 12 '24
Sale
57.84
7,300
422,232
7,002
Shuman Harry
VP Controller, PAO
Jun 10 '24
Sale
53.22
1,000
53,224
7,002
Shuman Harry
VP Controller, PAO
Jun 04 '24
Sale
52.89
6,000
317,354
7,002
Shuman Harry
VP Controller, PAO
Dec 19 '23
Sale
26.68
115
3,068
7,002
Silverman Peter B.
COO & GC
Dec 15 '23
Sale
25.00
22,386
559,650
0
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):